Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer

被引：1
|
作者：
Dasari, Arvind
Hubbard, Joleen M.
Eng, Cathy
Yeckes-Rodin, Heather
Ukrainskyj, Stacey M.
Yang, Zhao
Schelman, William R.
Kania, Marek K.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mayo Clin, Rochester, MN USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Cleveland Clin Florida, Port St Lucie, FL USA
[5] HUTCHMED Int, Shanghai, Peoples R China
[6] HUTCHMED Int, Florham Pk, NJ USA
[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
93
引用
收藏
页数：3
相关论文
共 50 条
  • [21] INTERIM RESULTS FOR PHASE 1B DOSE EXPANSION OF MTL-CEBPA IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMOUR MALIGNANCIES
    Plummer, Ruth
    Sodergren, Mikael
    Ryan, Brid
    Tachkov, Ilian
    Reebye, Vikash
    Meyer, Tim
    Pinato, David
    Sarker, Debashis
    Basu, Bristi
    Blagden, Sarah
    Cook, Natalie
    Evans, Jeff
    Yachnin, Jeffrey
    Chee, Cheng-Ean
    Li, Daneng
    El-Khoueiry, Anthony
    Diab, Maria
    Huang, Kai-Wen
    D'Alessio, Antonio
    Fulgenzi, Claudia
    Noel, Marcus
    Keenan, Bridget
    Mahalingam, Devalingam
    Raulf, Nina
    Hogson, Rose
    Tan, Choon Ping
    Nicholls, Joanna
    Adderkin, Alison
    Vassiliadou, Julia
    Habib, Robert
    Rossi, John
    Habib, Nagy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A888 - A889
  • [22] Interim update of the ATRC-101 phase 1b trial in advanced solid tumors
    Chmielowski, Bartosz
    Weroha, Saravut John
    Ulahannan, Susanna Varkey
    Doroshow, Deborah Blythe
    Valdes, Frances
    Bekaii-Saab, Tanios S.
    Powderly, John D.
    Recio-Boiles, Alejandro
    Berlin, Jordan
    Xing, Yan
    Khurana, Sudha
    Bishop, Philippe
    Isakoff, Steven J.
    Weinberg, Benjamin Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
    Disis, Mary L.
    Taylor, Matthew H.
    Kelly, Karen
    Beck, J. Thaddeus
    Gordon, Michael
    Moore, Kathleen M.
    Patel, Manish R.
    Chaves, Jorge
    Park, Haeseong
    Mita, Alain C.
    Hamilton, Erika P.
    Annunziata, Christina M.
    Grote, Hans Juergen
    von Heydebreck, Anja
    Grewal, Jaspreet
    Chand, Vikram
    Gulley, James L.
    JAMA ONCOLOGY, 2019, 5 (03) : 393 - 401
  • [24] Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
    Tarek Mekhail
    Hanspreet Kaur
    Ram Ganapathi
    G. Thomas Budd
    Paul Elson
    Ronald M. Bukowski
    Investigational New Drugs, 2006, 24 : 423 - 427
  • [25] Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
    Mekhail, T
    Kaur, H
    Ganapathi, R
    Budd, GT
    Elson, P
    Bukowski, RM
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (05) : 423 - 427
  • [26] Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
    Krishnamurthy, Anuradha
    Dasari, Arvind
    Noonan, Anne M.
    Mehnert, Janice M.
    Lockhart, Albert C.
    Leong, Stephen
    Capasso, Anna
    Stein, Mark N.
    Sanoff, Hanna K.
    Lee, James J.
    Hansen, Aaron
    Malhotra, Usha
    Rippke, Sarah
    Gustafson, Daniel L.
    Pitts, Todd M.
    Ellison, Kim
    Davis, S. Lindsey
    Messersmith, Wells A.
    Eckhardt, S. Gail
    Lieu, Christopher H.
    CANCER RESEARCH, 2018, 78 (18) : 5398 - 5407
  • [27] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [28] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [29] A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors
    Mita, Monica
    Baffa, Raffaele
    Charpentier, Eric
    Lockhart, Craig A.
    Morris, John C.
    Rixe, Olivier
    Sarantopoulos, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [30] PHASE 1B STUDY OF THE SRC INHIBITOR DASATINIB WITH FOLFOX AND CETUXIMAB IN REFRACTORY METASTATIC COLORECTAL CANCER
    Kopetz, S.
    Wolff, R.
    Eng, C.
    Overman, M.
    Henry, L.
    Coulson, R.
    Garrett, C.
    Abbruzzese, J.
    Gallick, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 15
12345